

# Optimizing antimicrobial treatment schedules: some fundamental analytical results

Guy Katriel  
Department of Applied Mathematics,  
Braude College of Engineering,  
Karmiel, Israel

## Abstract

This work studies fundamental questions regarding the optimal design of antimicrobial treatment protocols, using standard pharmacodynamic and pharmacokinetic mathematical models. We consider the problem of designing an antimicrobial treatment schedule to achieve eradication of a microbial infection, while minimizing the area under the time-concentration curve ( $AUC$ ). We first solve this problem under the assumption that an arbitrary antimicrobial concentration profile may be chosen, and prove that the *ideal* concentration profile consists of a constant concentration over a finite time duration, where explicit expressions for the optimal concentration and the time duration are given in terms of the pharmacodynamic parameters. Since antimicrobial concentration profiles are induced by a dosing schedule and the antimicrobial pharmacokinetics, the ideal concentration profile is not strictly feasible. We therefore also investigate the possibility of achieving outcomes which are close to those provided by the ideal concentration profile, using a bolus+continuous dosing schedule, which consists of a loading dose followed by infusion of the antimicrobial at a constant rate. We explicitly find the optimal bolus+continuous dosing schedule, and show that, for realistic parameter ranges, this schedule achieves results which are nearly as efficient as those attained by the ideal concentration profile. The optimality results obtained here provide a baseline and reference point for comparison and evaluation of antimicrobial treatment plans.

# 1 Introduction

Antimicrobial agents have made an immense contribution to human welfare, and their effective and efficient use is an issue of crucial importance [32, 38], in particular in view of the global antimicrobial resistance crisis, which is driven, in part, by mis-use or over-use [27, 42]. Mathematical modelling plays an important role in exploring the dynamics of microbial growth, antimicrobial pharmacokinetics and pharmacodynamics [28, 43]. Coupled with experimental laboratory work and clinical studies, mathematical modelling helps to design and evaluate treatment protocols and guidelines [5, 36, 35].

A traditional and widely-employed approach to the quantitative design of antimicrobial treatment regimens employs several PK/PD indices which quantify exposure over a time period, and uses experimental studies to determine the index which is maximally correlated to measures of efficacy for a particular antimicrobial, with respect to a specific microbial species [31, 32, 43]. A different methodology, known as ‘mechanism-based’ or ‘semi-mechanistic’ modelling [4, 9, 26, 28, 36] relies on modelling the full time-course of treatment using dynamic models which describe the time dependence of both the microbial population and the antimicrobial agent’s concentration, most often using differential equations. Such models include both pharmacokinetic parameters, related to drug distribution and elimination, and pharmacodynamic parameters, related to antimicrobial effect on the microbial population, and these parameters are estimated by fitting models to experimental data [3, 9, 15, 25, 28, 37, 44]. Once such a model is calibrated and validated, it can serve as an *in-silico* experimental system, allowing to test the outcomes of a variety of treatment schedules.

The availability of mechanism-based models raises the prospect of systematic determination of *optimal* treatment plans, using mathematical and computational approaches, and indeed several researchers have undertaken such investigations. The dynamical models used, as well as the class of candidate treatment schedules considered and the quantities targeted for optimization, vary among different works. Computationally intensive methods are used for the purpose of finding the optimal schedules, including optimal control methods [1, 16, 17, 34, 46], genetic algorithms [6, 7, 13, 14, 33] and machine learning [40]. While such computational work is very valuable and has the advantage of enabling the study of relatively elaborate models, it is also important to approach antimicrobial treatment optimization from an analytical point of view, with the aim of obtaining general insights and mathematical

results. Theoretical work of this type is, to the best of our knowledge, lacking in the literature, and the aim of this work is to take some steps to close this gap. By employing simple, but widely used, mathematical models, and by formulating natural optimization problems, we can mathematically prove several general results characterizing optimal treatment plans. An analytic approach provides generic results which are valid for *all* parameter values of a model, rather than for specific sets of parameters as in numerical studies, and enables to obtain useful explicit formulas for determining the quantities characterizing the optimal treatment regimens. The results yield fundamental understanding of the problem of optimal treatment with an antimicrobial agent. To the extent that the (standard) mathematical models used here capture the dynamics of microbial growth and the effect of antimicrobials, the results offer practical guidelines for the design of antimicrobial treatment schedules, as will be discussed.

We now provide an overview of the contributions presented in this paper, referring to the corresponding sections for details.

We formulate and address some key issues regarding optimal antimicrobial treatment. Stated simply (and to be formulated more precisely below), our question is:

Given that we aim to use an antimicrobial agent to eradicate a microbial infection, what is the treatment plan that will do so using a minimal cumulative dosage of antimicrobial?

The essential tradeoff underlying this optimization problem is that, while a low concentration of antimicrobial will be insufficient to suppress microbial growth, a very high concentration will be wasteful due to the saturation of the antimicrobial effect at high concentrations. To quantitatively illuminate this tradeoff, we use a standard pharmacodynamic model describing the growth of a microbial population and a killing rate of microbes depending on the antimicrobial concentration, see section 2. In the context of such a model, the microbial population size cannot reach 0, so that ‘eradication’ is defined in terms of reducing the microbial population size by a given factor, which will depend on the initial microbial population size.

Our work consists of two parts, in which we address the above question on two levels. In our first investigation (Sections 3-4) we allow an arbitrary time-dependence of the antimicrobial concentration at the infection site, and seek to find, among those concentration profiles which lead to eradication of the

microbial population, the one for which the area under the time-concentration curve ( $AUC$ ) is minimal. The  $AUC$  is a standard measure for the overall exposure [28], and indeed it is proportional to the cumulative antimicrobial dosage (see equation 5.2)). In this formulation of the problem, we are focusing on the pharmacodynamics, ignoring the fact that not every concentration profile is *pharmacokinetically feasible*, in the sense that it can be induced by an appropriate dosing schedule - these pharmacokinetic aspects are addressed in the second part of the paper. In this general context, we obtain several results:

- (i) We prove that the optimal antimicrobial concentration profile consists of a *constant* concentration  $c_{opt}$  applied for a finite time duration  $T_{opt}$ .
- (ii) We find an algebraic equation which allows us to determine the values  $c_{opt}$  and  $T_{opt}$ . In the case that the pharmacodynamics is described by a Hill function (the most commonly employed pharmacodynamic model) we solve this equation to obtain explicit expressions for  $c_{opt}$  and  $T_{opt}$  in terms of the pharmacodynamic parameters and the initial size of the microbial population (see section 4).
- (iii) We show that the optimal antimicrobial concentration  $c_{opt}$  is independent of the initial size of the microbial population, which only affects the duration  $T_{opt}$  of the optimal treatment.

The above results establish a *baseline* in the sense that they provide a lower bound for the  $AUC$  needed to achieve eradication. However, this analysis focuses only on the pharmacodynamics, that is the drug effect, ignoring the limitations on the concentration profile induced by pharmacokinetics - the dynamics of drug absorption and elimination. The ‘ideal’ concentration curve which achieves the lower bound, consisting of a constant concentration value over a finite time-interval, is not strictly achievable in practice, due to the simple fact that drug concentration cannot drop to 0 in a single instant, but rather decays in a gradual way. Therefore, in section 5, we address the question of achieving efficient treatment using drug concentration profiles which are *pharmacokinetically feasible*. We would like to achieve results which are close to the ‘ideal’ baseline determined in the first part of this work, but which can be realistically attained by a dosage plan, preferably one that is simple to implement. In this work we restrict ourselves to a simple one-compartment pharmacokinetic model - leaving consideration of more complex pharmacokinetics to future work. The only pharmacokinetic parameter is thus the rate

of drug decay. In this context, we examine simple dosage plans of the *bolus+continuous* type [10], in which a single (bolus) dose of the antimicrobial is given at the initiation of treatment, in order to instantaneously raise the drug concentration to a level  $\bar{c}$ , and constant-rate infusion is provided thereafter, for a time duration  $T_{bc}$ , in order to maintain the same concentration. The initial dose and the constant rate of infusion are determined by the desired concentration and the pharmacokinetic parameter (rate of drug decay). This choice of dosing schedule mimicks the ‘ideal’ concentration profile in that the concentration is constant for a finite duration, but with exponential decay thereafter. Optimizing over all such dosing schedules (that is over all choices of  $\bar{c}$  and  $T_{bc}$ ) which achieve eradication, with the aim of minimizing the *AUC* (which is equivalent to minimizing total dosage), we find the following:

- (i) The optimal concentration  $\bar{c}$  is (somewhat surprisingly) identical to the value  $c_{opt}$  obtained for the ‘ideal’ concentration profile in the first part of our work. In particular, it does not depend on the pharmacokinetics, that is on the rate of decay of the antimicrobial.
- (ii) The optimal time duration  $T_{bc,opt}$  over which the constant-rate infusion of drug should be performed is given by an explicit formula, and depends both on the pharmacodynamics and on the rate of decay of the antimicrobial. This duration is always shorter than the duration  $T_{opt}$  of the ‘ideal’ concentration profile.
- (iii) If the antimicrobial decay rate is sufficiently small, then  $T_{bc} = 0$ , that is the optimal bolus+continuous schedule consists only of a bolus dose, and if the antimicrobial decay rate is large, then  $T_{bc}$  is close to  $T_{opt}$ , and the *AUC* corresponding to the optimal bolus+continuous treatment is close to (though somewhat higher than) the *AUC* of the ‘ideal’ concentration profile.

Numerical results given in section 6, computed for the case of a Hill-type pharmacodynamic function, with realistic ranges of values of the pharmacokinetic and pharmacodynamic parameters, show that, in most cases, the optimal bolus+continuous dosing schedule achieves results which are nearly as efficient as those attained using the ‘ideal’ concentration profile, in that the *AUC* valued attained is not significantly higher. We thus conclude that a bolus+continuous schedule, suitably designed, provides a nearly-optimal solution under many circumstances.

While the results obtained here provide what we believe to be an essential theoretical basis for thinking about the optimization of antimicrobial treatments, there are various complicating issues that should be taken into account in considering the application of these results in concrete settings. In Section 7 we address some of the limitations of the standard modelling framework employed in this work, and suggest directions for further investigation.

## 2 The pharmacodynamic model

In this section we describe the modelling framework which will be employed to study antimicrobial treatment schedules, which is standard in the field of pharmacodynamics [2, 3, 4, 8, 13, 14, 15, 25, 28, 29, 30]. The notation to be used is summarized in Table 1.

An antimicrobial treatment schedule will determine a function  $C(t)$  ( $t \geq 0$ ) describing the concentration of antimicrobial at the infection site as a function of time  $t$ , which we will call the *concentration profile*. We allow  $C(t)$  to be an arbitrary non-negative function in the class  $L^1[0, \infty)$  of integrable functions.

The area under the concentration curve

$$AUC = \int_0^{\infty} C(t)dt, \quad (2.1)$$

is a standard measure of the intensity of the antimicrobial treatment. Indeed it may be seen that the  $AUC$  is proportional to the cumulative dosage of the antimicrobial supplied, see equation (5.2) in section 5.

Denoting by  $B(t)$  the size of the microbial population at time  $t$ , we use the standard constant-rate model of microbial growth in the absence of treatment

$$\frac{dB}{dt} = rB,$$

where  $r$  is the difference of the replication rate and the natural death rate, leading to exponential growth, with doubling time

$$T_2 = \frac{\ln(2)}{r}. \quad (2.2)$$

The antimicrobial effect is modelled using a function  $k(c)$ , known as the pharmacodynamic function [37], or the kill curve [26], which describes the

kill-rate of the antimicrobial agent at concentration  $c$ . In the presence of antimicrobial, the microbial population is thus described by

$$\frac{dB}{dt} = [r - k(C(t))]B, \quad (2.3)$$

with solution

$$B(t) = B_0 \cdot e^{\int_0^t [r - k(C(s))] ds}, \quad (2.4)$$

where  $B_0$  is the initial microbial population size at time  $t = 0$ .

The kill-rate function  $k(c)$  will be assumed to have the following properties

(A1)  $k(0) = 0$ , and  $k(c)$  is continuous and monotone increasing on  $[0, \infty)$ , and twice differentiable for  $c > 0$ .

(A2) The kill rate saturates at high concentrations:

$$\lim_{c \rightarrow \infty} k(c) = k_{max} < \infty. \quad (2.5)$$

We will also make one of the following two assumptions regarding the shape of the function  $k(c)$ :

**Definition 1.** (i)  $k(c)$  will be said to be **concave** if  $k''(c) < 0$  for all  $c \geq 0$ .

(ii)  $k(c)$  will be said to be **sigmoidal** if there exists a value  $c_{infl} > 0$  (the inflection point) so that

$$0 \leq c < c_{infl} \Rightarrow k''(c) > 0 \quad \text{and} \quad c > c_{infl} \Rightarrow k''(c) < 0.$$

**Example 1.** The most common functional form used for the pharmacodynamic function is the Hill function (also known as the Sigmoid Emax model [23] or the Zhi model [8, 45])

$$k_H(c) = k_{max} \cdot \frac{c^\gamma}{C_{50}^\gamma + c^\gamma}, \quad (2.6)$$

where the  $\gamma > 0$  is called the Hill exponent and  $C_{50}$  is the half-saturation constant, the concentration at which the kill rate is half of the maximal value  $k_{max}$ . In the survey [9] one may find tables with estimates of the parameters  $C_{50}, k_{max}, \gamma$  for various combinations of antimicrobials and microbial species, obtained through many empirical studies.

The function  $k_H(c)$  is concave if  $\gamma \leq 1$ , and sigmoidal if  $\gamma > 1$ , in which case the inflection point is given by

$$c_{infl} = C_{50} \cdot \left( \frac{\gamma - 1}{\gamma + 1} \right)^{\frac{1}{\gamma}}.$$

Our main results do not depend on this specific functional form, but we will apply the general results to this specific example, and obtain useful explicit expressions - see in particular section 4.

It will be useful to introduce the dimensionless parameter

$$\alpha = \frac{k_{max}}{r}, \tag{2.7}$$

measuring the maximal kill-rate of the antimicrobial relative to the natural microbial growth rate, which we will therefore call the *potency* of the antimicrobial with respect to a microbial species. We will make the standing assumption that

$$\alpha > 1, \tag{2.8}$$

that is  $k_{max} > r$ , which means that a sufficiently large concentration will lead to a negative net growth rate of the microbial population - if this is not the case then the antimicrobial is not effective. Under this assumption, and in view of the assumption (A1) above, there exists a unique value of  $c$ , denoted by  $zMIC$ , the pharmacodynamic minimal inhibitory concentration [4, 8], also referred to as the stationary concentration (SC) [25, 9], such that

$$k(zMIC) = r. \tag{2.9}$$

**Example 2.** In the case that the kill-rate is given by a Hill function (2.6), we have

$$zMIC = C_{50} \cdot (\alpha - 1)^{-\frac{1}{\gamma}}. \tag{2.10}$$

Note that within the framework of model (2.3) the microbial population cannot be reduced to 0, since  $B(t)$  given by (2.4) is always positive, and indeed if  $AUC$  is finite then for large time the microbial population will recover, with  $B(t) \rightarrow +\infty$  as  $t \rightarrow \infty$ . However, in practice, reaching a sufficiently low value of  $B(t)$  at some point in time, *e.g.* corresponding to less than one organism, implies eradication. The appropriate measure for the success of treatment is therefore the *maximal* reduction in the size of the



microbial population achieved at some time. The reduction is standardly expressed on a logarithmic scale, by defining the log-reduction at time  $T$

$$LR(T) = \log_{10} \left( \frac{B_0}{B(T)} \right) = \frac{1}{\ln(10)} \cdot \ln \left( \frac{B_0}{B(T)} \right),$$

(we use base 10 in order to be consistent with the literature) which in view of (2.4) is given by

$$LR(T) = \frac{1}{\ln(10)} \cdot \int_0^T [k(C(t)) - r] dt. \quad (2.11)$$

The *maximal* reduction afforded by the concentration profile  $C(t)$  is then

$$LR_{max} = LR_{max}[C] = \max_{T \geq 0} LR(T). \quad (2.12)$$

We note that, since  $LR(0) = 0$  and  $\lim_{T \rightarrow \infty} LR(T) = -\infty$ , the maximum in (2.12) certainly exists.

Eradication of the infection thus corresponds to achieving  $LR_{max}[C] \geq LR_{target}$ , where the value of  $LR_{target}$  is given.

Symbol	Description
$B(t)$	Microbial population size at time $t$ .
$B_0$	Initial microbial population size.
$C(t)$	Antimicrobial concentration at time $t$ .
$AUC$	Area under the time-concentration curve $C(t)$ , see (2.1).
$r$	Microbial growth rate in absence of antimicrobial.
$T_2 = \frac{\ln(2)}{r}$	Microbial doubling time in absence of antimicrobial.
$k(c)$	Kill-rate of antimicrobial, in dependence on its concentration.
$k_{max}$	Maximal kill-rate of antimicrobial, see (2.5).
$\alpha = \frac{k_{max}}{r}$	Antimicrobial potency relative to a microbial species.
$c_{infl}$	Inflection point of $k(c)$ , in the sigmoidal case.
$zMIC$	Pharmacodynamic minimal inhibitory concentration, see (2.9).
$k_H(c)$	Hill model for kill-rate, see (2.6)
$\gamma$	Hill exponent, see (2.6)
$C_{50}$	Half saturation constant for Hill model, see (2.6)
$LR(T)$	$\log$ (base 10) reduction of microbial population at time $T$ , see (2.11).

$LR_{max}[C]$	Maximal log reduction of microbial population corresponding to a given concentration profile, see (2.12).
$LR_{target}$	Target log reduction on microbial population for achieving eradication.
$LR_{opt}$	Maximal log reduction attainable by a concentration profile with given $AUC$ , given by (3.5).
$C_{opt}(t)$	Optimal antimicrobial concentration profile, see Theorem 1.
$c_{opt}$	Optimal antimicrobial concentration, see Theorem 1.
$T_{opt}$	Duration of optimal concentration profile, see (3.3).
$AUC_{opt}$	Minimal $AUC$ attainable by any antimicrobial concentration profile, given by (3.4).
$\kappa$	Antimicrobial decay rate.
$\tau = \frac{\ln(2)}{\kappa}$	Antimicrobial half-life.
$d(t)$	Antimicrobial dosing rate at time $t$ .
$d_{bc}(t)$	bolus+continuous dosing schedule, see (5.4).
$d_{bc,opt}(t)$	optimal bolus+continuous dosing schedule, see (5.7).
$T_{bc}$	Duration of dosing for a bolus+continuous schedule.
$T_{bc,opt}$	Duration of the optimal dosing of bolus+continuous type, see (5.21).

---

Table 1: Notation

### 3 Optimizing treatment: the ‘ideal’ concentration profile

Our aim is to choose a concentration profile  $C(t)$ , among *all* non-negative integrable functions on  $[0, \infty)$ , so as to minimize the  $AUC$ , while achieving a specified log-reduction of the microbial load. We therefore formulate:

**Problem 1.** *Given a target value  $LR_{target}$ , find a concentration profile  $C(t)$  achieving  $LR_{max}[C] = LR_{target}$ , where  $LR_{max}$  is given by (2.12), with the corresponding  $AUC$  (given by (2.1)) as small as possible.*

The following theorem provides a complete solution to this problem.

**Theorem 1.** *Assume a value  $LR_{target}$  is given. The unique solution of Problem 1 is given by the concentration profile*

$$C_{opt}(t) = \begin{cases} c_{opt} & 0 \leq t \leq T_{opt} \\ 0 & t > T_{opt} \end{cases}, \quad (3.1)$$

where  $c_{opt}$  is the unique solution of the equation

$$k'(c) = \frac{k(c) - r}{c}, \quad (3.2)$$

and

$$T_{opt} = \frac{\ln(10) \cdot LR_{target}}{k(c_{opt}) - r}, \quad (3.3)$$

giving the minimal value of  $AUC$

$$AUC_{opt} = T_{opt} \cdot c_{opt} = \ln(10) \cdot LR_{target} \cdot \frac{c_{opt}}{k(c_{opt}) - r}. \quad (3.4)$$

Several notable consequences emerge from Theorem 1:

- (i) The ‘ideal’ dosing strategy is to keep the concentration of antimicrobial *constant* at  $c_{opt}$  for the duration of time determined by  $T_{opt}$ .
- (ii) By (3.2),  $c_{opt}$  depends only on the microbial growth rate  $r$  and on the kill-rate function  $k(c)$ , and not on the target reduction  $LR_{target}$ . Thus the given target reduction affects the optimal schedule only through its effect on the duration  $T_{opt}$ , which, by (3.3), depends linearly on  $LR_{target}$ .
- (iii) By (3.4), the minimal achievable  $AUC$  depends linearly on the target reduction  $LR_{target}$ .

We note that equation (3.2) leads to a graphical construction for obtaining the optimal concentration  $c_{opt}$  - see figure 1.

In section 4 the results of Theorem 1 will be applied to the standard Hill-type form of the killing curve, leading to explicit expressions for  $c_{opt}$ ,  $T_{opt}$ .

We have formulated our problem and solution in terms of minimizing the  $AUC$  subject to achieving a given log-reduction  $LR_{target}$ , but an equivalent




Figure 1: Graphical construction of the optimal concentration  $c_{opt}$ . Plot the straight line which passes through the point  $(0, r)$  and is tangent to the curve  $k(c)$ . The abscissa at the tangency point is the value  $c_{opt}$ . In this plot we use the Hill curve with  $\gamma = 3$ ,  $C_{50} = 1$ ,  $k_{max} = 1$ ,  $r = 0.4$ .

problem is to maximize the log-reduction  $LR_{max}$  subject to a given  $AUC$  - since  $AUC$  is proportional to the total dosage this problem will arise if we want to maximize the efficacy of a given total dose of the antimicrobial. We can re-formulate the result of Theorem 1 as follows:

**Corollary 1.** *Given a value  $AUC$ , the concentration profile  $C(t)$  satisfying  $AUC[C] = AUC$  and inducing the maximal log-reduction  $LR_{max}[C]$  is given by (3.1), where  $c_{opt}$  is the unique solution of (3.2), and*

$$T_{opt} = \frac{AUC}{c_{opt}}.$$

The value of  $LR_{max}$  attained by this optimal profile is

$$LR_{opt} = \frac{1}{\ln(10)} \cdot \frac{k(c_{opt}) - r}{c_{opt}} \cdot AUC. \quad (3.5)$$

The rest of this section is devoted to the proof of Theorem 1.

As a first step in the analysis leading to Theorem 1, we consider only the specific class of concentration profiles which take a constant value  $c$  for

a duration  $T_f$  (the final time), that is:

$$C(t) = \begin{cases} c & 0 \leq t \leq T_f \\ 0 & t > T_f \end{cases} \quad (3.6)$$

Among these profiles, we will now find the one which achieves the log-reduction  $LR_{target}$  with minimal  $AUC$ . Later we will prove that the resulting concentration profile is in fact optimal among *all* concentration profiles satisfying  $LR_{max}[C] = LR_{target}$ .

The log-reduction up to an arbitrary time  $T \geq 0$ , corresponding the concentration profile (3.6), is (see (2.11))

$$LR(T) = \frac{1}{\ln(10)} \cdot \int_0^T [k(C(t)) - r] dt = \frac{1}{\ln(10)} \cdot \begin{cases} T \cdot (k(c) - r) & T \leq T_f \\ T_f \cdot k(c) - T \cdot r & T > T_f \end{cases},$$

which is increasing for  $T \leq T_f$  and decreasing for  $T \geq T_f$ , hence

$$LR_{max} = \max_{T \geq 0} LR(T) = LR(T_f) = \frac{1}{\ln(10)} \cdot T_f \cdot (k(c) - r).$$

Therefore to achieve a target log-reduction  $LR_{target}$  using the constant concentration  $c$  we need to choose

$$T_f = \frac{\ln(10) \cdot LR_{target}}{k(c) - r}. \quad (3.7)$$

The  $AUC$  corresponding to this profile is

$$AUC = T_f \cdot c = \ln(10) \cdot LR_{target} \cdot \frac{c}{k(c) - r}.$$

Thus to minimize the  $AUC$  we need to maximize the function  $f_r : (0, \infty) \rightarrow \mathbb{R}$  defined by

$$f_r(c) = \frac{k(c) - r}{c} \quad (3.8)$$

over all  $c > 0$ . The existence of this maximizer, and the fact that it is the unique critical point of  $f_r$ , is shown in the following Lemma:

**Lemma 1.** *Assume  $0 \leq r < k_{max}$ . The function  $f_r$  defined by (3.8) has a unique critical point  $c_{opt}$ , that is a value satisfying*

$$f'_r(c) = 0 \Leftrightarrow k'(c) = \frac{k(c) - r}{c}, \quad (3.9)$$

which is a global maximizer of  $f_r$ .

In the sigmoidal case (see definition 1), we always have  $c_{opt} > c_{infl}$ , where  $c_{infl}$  is the inflection point of  $k(c)$ .

*Proof of Lemma 1.* We have, for any  $r > 0$ ,

$$c < zMIC \Rightarrow f_r(c) < 0, \quad c > zMIC \Rightarrow f_r(c) > 0,$$

$$\lim_{c \rightarrow +\infty} f_r(c) = 0.$$

These facts imply that  $f_r(c)$  has a global maximizer on  $(0, \infty)$ , which we denote by  $c_{opt}$ . It remains to show that  $c_{opt}$  is the unique critical point of  $f_r(c)$ . We have

$$f'_r(c) = \frac{k'(c) - \frac{k(c)}{c}}{c} + \frac{r}{c^2} = \frac{h(c) + r}{c^2} \quad (3.10)$$

where

$$h(c) = ck'(c) - k(c), \quad (3.11)$$

so any critical point of  $f_r(c)$  satisfies  $h(c) = -r$ . Note that

$$h'(c) = ck''(c), \quad (3.12)$$

hence:

(a) if  $k$  is concave then  $h'(c) < 0$ , so  $h(c)$  is decreasing in  $(0, \infty)$ , hence the critical point  $c_{opt}$  of  $f_r(c)$  is unique.

(b) If  $k$  is sigmoidal, then  $h'(c) < 0$  for  $c > c_{infl}$ , hence  $h(c)$  is decreasing in this range, so that  $f_r(c)$  has at most one critical point in the interval  $[c_{infl}, \infty)$ . To prove uniqueness it therefore suffices to show that  $f_r(c)$  has no critical point in  $[0, c_{infl}]$ . But note that since  $k(c)$  is convex on  $[0, c_{infl}]$ , hence  $k'(c)$  is increasing on this interval, we have

$$c \in (0, c_{infl}] \Rightarrow k'(c) = \frac{1}{c} \int_0^c k'(c) du > \frac{1}{c} \int_0^c k'(u) du = \frac{k(c)}{c}, \quad (3.13)$$

hence, by (3.10),  $f'_r(c) > 0$  for  $c \in (0, c_{infl}]$ . Note that this also shows that  $c_{opt} > c_{infl}$ .  $\square$

The above considerations show that the optimal concentration profile, among those of the form (3.6) which achieve  $LR_{target}$ , is given by (3.1), with  $c_{opt}$  given by (3.2), and  $T_{opt}$  given by (3.3).

We now show that the profile  $C_{opt}(t)$  is in fact optimal among *all* concentration profiles which achieve  $LR_{target}$ , and is thus the solution to Problem 1:

*Proof of Theorem 1:* Let  $C(t)$  be any concentration profile with  $LR_{max}[C] = LR_{target}$ , and let  $T^* \geq 0$  be the value for which  $LR(T^*) = LR_{max}[C]$ . We then have

$$\begin{aligned} \ln(10) \cdot LR_{target} &= \ln(10) \cdot LR(T) = \int_0^{T^*} C(t) \cdot \frac{k(C(t)) - r}{C(t)} dt \quad (3.14) \\ &\leq \left[ \max_c \frac{k(c) - r}{c} \right] \cdot \int_0^{T^*} C(t) dt \\ &\leq \left[ \max_c \frac{k(c) - r}{c} \right] \cdot \int_0^\infty C(t) dt = \frac{k(c_{opt}) - r}{c_{opt}} \cdot AUC \end{aligned}$$

so that

$$AUC \geq \ln(10) \cdot \frac{c_{opt} \cdot LR_{target}}{k(c_{opt}) - r} = AUC_{opt}, \quad (3.15)$$

so we see that  $AUC$  cannot be made smaller than the value (3.4) obtained by taking the concentration profile  $C_{opt}(t)$ . Therefore  $C_{opt}(t)$  is a minimizer.

To show uniqueness of the minimizer, note that if we have equality in (3.15), hence in (3.14), then it must be the case that

$$\frac{k(C(t)) - r}{C(t)} = \max_c \frac{k(c) - r}{c},$$

implying that  $C(t) = c_{opt}$ , for almost every  $t \in [0, T^*]$ , as well as that

$$\int_0^{T^*} C(t) dt = \int_0^\infty C(t) dt,$$

implying that  $C(t) = 0$  for a.e.  $t \geq T^*$ . We therefore have

$$LR_{max}[C] = \frac{1}{\ln(10)} \cdot T^* \cdot (k(c_{opt}) - r),$$

implying that

$$T^* = \frac{\ln(10) LR_{target}}{k(c_{opt}) - r} = T_{opt}.$$

We have thus shown that  $C(t) = C_{opt}(t)$  for a.e.  $t$ , establishing uniqueness.  $\square$

## 4 Application to Hill-type pharmacodynamic functions

We now specialize the results to the case that the kill-rate function is the Hill function  $k_H(c)$  defined by (2.6), which allows us to obtain explicit expressions for the quantities of interest. We use these expressions to study the dependence of  $c_{opt}$  and  $T_{opt}$  on the relevant parameters.

In the case of a Hill-type pharmacodynamic function (3.8) gives

$$f_r(c) = \frac{1}{c} \left( k_{max} \cdot \frac{c^\gamma}{C_{50}^\gamma + c^\gamma} - r \right) = \frac{r}{c} \left( \alpha \cdot \frac{c^\gamma}{C_{50}^\gamma + c^\gamma} - 1 \right),$$

where  $\alpha$  is the antimicrobial potency given by (2.7). Solving the equation  $f'_r(c) = 0$ , which is equivalent to

$$(\alpha - 1)c^{2\gamma} - ((\gamma - 1)\alpha + 2)c^\gamma - 1 = 0,$$

we find that the optimal concentration is

$$c_{opt} = c_{opt}(\gamma, \alpha) = C_{50} \cdot (\alpha - 1)^{-\frac{1}{\gamma}} \cdot \left[ \frac{\gamma - 1}{2} \cdot \alpha + 1 + \sqrt{\left( \frac{\gamma - 1}{2} \cdot \alpha \right)^2 + \gamma \cdot \alpha} \right]^{\frac{1}{\gamma}}, \quad (4.1)$$

giving a kill rate of

$$k_H(c_{opt}) = k_{max} \cdot \left( 1 - \frac{\alpha - 1}{\frac{\gamma+1}{2} \cdot \alpha + \sqrt{\left( \frac{\gamma-1}{2} \cdot \alpha \right)^2 + \gamma \cdot \alpha}} \right),$$

and from (3.3) we find that the time  $T_{opt}$  for which this concentration should be maintained is

$$T_{opt} = T_{opt}(\gamma, \alpha) = T_2 \cdot \frac{\ln(10)LR_{target}}{\ln(2)(\alpha - 1)} \cdot \left( 1 + \frac{\alpha}{\frac{\gamma-1}{2} \cdot \alpha + \sqrt{\left( \frac{\gamma-1}{2} \cdot \alpha \right)^2 + \gamma \cdot \alpha}} \right), \quad (4.2)$$

where  $T_2$  is the microbial doubling time in the absence of antimicrobial (see (2.2)).

Note that:



- The optimal concentration  $c_{opt}$  is linearly dependent on the half-saturation concentration  $C_{50}$ . Therefore in our presentation of numerical results below we provide the values of the dimensionless ratio  $\frac{C_{opt}}{C_{50}}$ .
- The optimal duration  $T_{opt}$  is linearly dependent on the target log-reduction  $LR_{target}$ , as well as on the microbial doubling time  $T_2$ . Therefore in presentation of numerical results we provide the values of the dimensionless ratio  $\frac{T_{opt}}{T_2}$ . Note that  $T_{opt}$  does *not* depend on the value of the half-saturation constant  $C_{50}$ .
- As a consequence of the above and of (3.4), the value  $AUC_{opt}$  depends linearly on both  $T_2$  and  $C_{50}$ , so that in the presentation of numerical results we provide the value of the dimensionless ratio  $\frac{AUC}{T_2 \cdot C_{50}}$ .

Table 2 presents the optimal concentration, duration, and  $AUC$  for parameter values in the range which is typical for most antimicrobials. According to studies estimating parameters for various antimicrobials, reviewed in [9], the Hill coefficient of  $\gamma$  is in most cases in the range 0.5 – 5, and the potency  $\alpha = \frac{k_{max}}{r}$  is mostly in the range 2 – 6. In the calculation of  $T_{opt}$  and  $AUC_{opt}$  we have taken  $LR_{target} = 7$  – in view of the linear dependence of these quantities on  $LR_{target}$ , to obtain  $T_{opt}$ ,  $AUC_{opt}$  for any value of  $LR_{target}$  one simply needs to multiply the value in the table by  $\frac{LR_{target}}{7}$ .

We can use the explicit expressions (4.1),(4.2) to study the nature of the dependence of  $c_{opt}$  and  $T_{opt}$  on the drug potency  $\alpha$  and the Hill exponent  $\gamma$ . The results are given in Propositions 1,2 - we omit the derivation of these results since they are routine applications of elementary calculus arguments.

The following proposition shows that higher antimicrobial potency  $\alpha$  leads the optimal concentration profile to involve both a lower concentration and a shorter duration (see also figure 2).

**Proposition 1.** (a) For fixed  $\gamma > 0$ , the function  $c_{opt}(\alpha) = c_{opt}(\gamma, \alpha)$  ( $\alpha > 1$ ) is monotone decreasing, with

$$\lim_{\alpha \rightarrow 1^+} c_{opt}(\alpha) = +\infty. \quad (4.3)$$

and

(i) In the concave case  $\gamma \leq 1$ :  $\lim_{\alpha \rightarrow \infty} c_{opt}(\alpha) = 0$ .

(ii) In the sigmoidal case  $\gamma > 1$ :  $\lim_{\alpha \rightarrow \infty} c_{opt}(\alpha) = C_{50} \cdot (\gamma - 1)^{\frac{1}{\gamma}} > 0$ .




Figure 2: The parameters defining the optimal concentration profile as functions of  $\alpha = \frac{k_{max}}{r}$ , for different values of the Hill exponent. Left: the ratio of  $c_{opt}$  to the half-saturation value  $C_{50}$  of the antimicrobial. Right: the ratio of  $T_{opt}$  to the microbial doubling time  $T_2$ . Here it is assumed that  $LR_{target} = 7$ .

(b) For fixed  $\gamma > 0$ , the function  $T_{opt}(\alpha) = T_{opt}(\gamma, \alpha)$  ( $\alpha > 1$ ) is monotone decreasing, with

$$\lim_{\alpha \rightarrow 1^+} T_{opt}(\alpha) = +\infty, \quad \lim_{\alpha \rightarrow \infty} T_{opt}(\alpha) = 0. \quad (4.4)$$

The dependence of  $c_{opt}$ ,  $T_{opt}$  on the Hill exponent  $\gamma$  is described in the next proposition. Note that the shape of the function  $c_{opt}(\gamma)$  is different for  $\alpha < 2$ ,  $\alpha = 2$ , and  $\alpha > 2$  - see also figure 3.

**Proposition 2.** (a) For fixed  $\alpha > 1$ , the function  $c_{opt}(\gamma) = c_{opt}(\gamma, \alpha)$  satisfies

$$\lim_{\gamma \rightarrow \infty} c_{opt}(\gamma) = C_{50}, \quad (4.5)$$

and

- (i) If  $1 < \alpha < 2$  then  $c_{opt}(\gamma)$  is monotone decreasing, with  $\lim_{\gamma \rightarrow 0^+} c_{opt}(\gamma) = +\infty$ .
- (ii) If  $\alpha = 2$ , then  $c_{opt}(\gamma)$  is monotone decreasing, with  $\lim_{\gamma \rightarrow 0^+} c_{opt}(\gamma) = e \cdot C_{50}$ .

Optimal concentration  $\frac{c_{opt}}{C_{50}}$

		$\alpha$				
		2	3	4	5	6
$\gamma$	0.5	2.62	0.71	0.33	0.19	0.13
	1	2.41	1.37	1.00	0.81	0.69
	2	2.06	1.64	1.47	1.37	1.31
	3	1.83	1.60	1.51	1.46	1.42
	4	1.69	1.54	1.48	1.44	1.42
	5	1.59	1.48	1.43	1.41	1.39

Optimal duration  $\frac{T_{opt}}{T_2}$

		$\alpha$				
		2	3	4	5	6
$\gamma$	0.5	98.5	62.5	50.1	43.8	39.9
	1	56.1	31.8	23.3	18.8	16.0
	2	37.6	19.6	13.4	10.3	8.3
	3	32.3	16.4	11.1	8.4	6.7
	4	29.8	15.1	10.1	7.6	6.1
	5	28.4	14.3	9.6	7.2	5.8

$\frac{AUC_{opt}}{T_2 \cdot C_{50}}$

		$\alpha$				
		2	3	4	5	6
$\gamma$	0.5	257.9	44.4	16.7	8.5	5.1
	1	135.5	43.4	23.3	15.2	11.1
	2	77.4	32.1	19.7	14.1	10.9
	3	59.1	26.4	16.7	12.2	9.6
	4	50.3	23.1	14.9	11.0	8.7
	5	45.0	21.1	13.7	10.1	8.0

Table 2: Optimal concentration profiles for different values of  $\alpha = \frac{k_{max}}{r}$  and of the Hill exponent  $\gamma$ . Top: Optimal concentration  $\frac{c_{opt}}{C_{50}}$ , Middle: optimal duration  $\frac{T_{opt}}{T_2}$  for achieving log-reduction  $LR_{target} = 7$ . Bottom: value of  $\frac{AUC}{T_2 \cdot C_{50}}$  attained by the optimal schedule, assuming  $LR_{target} = 7$ .




Figure 3: The parameters defining the optimal concentration profile functions of  $\gamma$ , for different values of the potency  $\alpha$ . Left: the ratio of  $c_{opt}$  to the half-saturation value  $C_{50}$  of the antimicrobial. Right: the ratio of  $T_{opt}$  to the microbial doubling time  $T_2$ . Here it is assumed that  $LR_{target} = 7$ .

(iii) If  $\alpha > 2$ , then  $c_{opt}(\gamma)$  is increasing for small  $\gamma$  and decreasing for large  $\gamma$ , and  $\lim_{\gamma \rightarrow 0^+} c_{opt}(\gamma) = 0$ .

(b) For any  $\alpha > 1$ , the function  $T_{opt}(\gamma) = T_{opt}(\gamma, \alpha)$  is monotone decreasing, with

$$\lim_{\gamma \rightarrow 0^+} T_{opt}(\gamma) = +\infty, \quad \lim_{\gamma \rightarrow \infty} T_{opt}(\gamma) = 0.$$

## 5 Pharmacokinetic considerations: the optimal bolus+continuous dosing schedule

In the preceding analysis we considered arbitrary antimicrobial concentration profiles  $C(t)$ . In practice, however, the concentration profile cannot be chosen at will, since it is the result of a dosage plan and of the pharmacokinetics of the drug. Thus, while the concentration profile given by Theorem 1 is the optimal one, we show below that it is impossible to achieve this profile precisely, due the fact that the optimal profile  $C_{opt}(t)$  has a discontinuity at  $t = T_{opt}$ , while realistic pharmacokinetics precludes such a sharp cutoff. It then becomes of interest to approximate the ‘ideal’ concentration profile, to

the extent possible, by a *pharmacokinetically feasible* one. We will consider one simple and natural method of doing so, and determine its optimal version.

We assume a basic one-compartment pharmacokinetic model with first order degradation kinetics - a reasonable choice for most commonly prescribed antimicrobials [4]. The dosing rate - the rate at which antimicrobial is added into the compartment, will be denoted by  $d(t)$ . The concentration profile is then given by the solution of the differential equation

$$\frac{dC}{dt} = V^{-1}d(t) - \kappa C(t), \quad C(0) = 0, \quad (5.1)$$

where  $V$  is the volume of distribution and  $\kappa$  is the degradation/removal rate of the antimicrobial, so that

$$\tau = \frac{\ln(2)}{\kappa}$$

is the antimicrobial half-life. Making the natural assumption that the cumulative dose

$$D = \int_0^{\infty} d(t)dt$$

is finite, it follows that  $C(\infty) = \lim_{t \rightarrow \infty} C(t) = 0$ , so that, by integrating (5.1) over  $[0, \infty)$  we obtain

$$0 = C(\infty) - C(0) = V^{-1} \int_0^{\infty} d(t)dt - \kappa \cdot AUC$$

hence

$$AUC = \kappa^{-1}V^{-1}D. \quad (5.2)$$

Note that this shows that the objective of minimizing the  $AUC$  is equivalent to that of minimizing the cumulative dose. An analogous linear relation between cumulative dosage  $D$  and  $AUC$  can be derived for more complicated (multi-compartment) pharmacokinetics.

The solution of (5.1) is given by

$$C(t) = V^{-1} \int_0^t e^{-\kappa(t-s)} d(s)ds. \quad (5.3)$$

We note that (5.3) is meaningful even if  $d(t)$  is not a function, but is rather an arbitrary non-negative measure - and may therefore include  $\delta$ -functions which represent *bolus doses*, that is a finite amount of antimicrobial which

is injected instantaneously, as we shall do below. In any case,  $C(t)$  given by (5.3) will always be continuous and positive for all  $t > 0$  sufficiently large, so that the function  $C_{opt}(t)$  given by (3.1) cannot be represented in the form (5.3), that is, it is not pharmacokinetically feasible.

We can, however, generate concentration profiles which take a constant value  $\bar{c}$  for duration  $0 \leq t \leq T_{bc}$  by administering a bolus loading dose of size  $V\bar{c}$ , at time  $t = 0$  to raise the concentration to  $\bar{c}$ , and thereafter supplying the drug as a continuous infusion at rate  $\kappa V\bar{c}$  up to time  $T_{bc}$ , so as to maintain the concentration  $\bar{c}$ . This is known as a *bolus+continuous (bc)* dosage schedule [10]. Note that in order to achieve reduction in the microbial load we must take  $\bar{c} > zMIC$ . The expression for this dosing schedule is thus

$$d_{bc}(t) = V\bar{c} \cdot [\delta(t) + \kappa \cdot H(T_{bc} - t)], \quad (5.4)$$

where the  $\delta$ -function represents the bolus dose, and  $H$  is the Heaviside function:  $H(t) = 0$  for  $t < 0$  and  $H(t) = 1$  for  $t \geq 0$ .

The resulting concentration profile, given by the solution of (5.1), will be

$$C_{bc}(t) = \begin{cases} \bar{c} & t \leq T_{bc} \\ \bar{c}e^{-\kappa(t-T_{bc})} & t > T_{bc}. \end{cases} \quad (5.5)$$

We now formulate and study the problem of optimizing a bolus+continuous dosing schedule.

**Problem 2.** *Among all dosing schedules of the form (5.4), parameterized by  $\bar{c}$  and  $T_{bc}$ , for which the corresponding log-reduction is  $LR_{max}[C_{bc}] = LR_{target}$ , find the one for which the AUC is minimal.*

The solution of this problem is given by

**Theorem 2.** *Define*

$$\rho = \int_{zMIC}^{c_{opt}} \frac{k(u) - r}{u} du, \quad (5.6)$$

where  $zMIC$  is the solution of (2.9) and  $c_{opt}$  is the solution of (3.2).

*Then:*

(i) *If  $\rho < \ln(10)LR_{target} \cdot \kappa$ , then the solution of Problem 2 is given by*

$$d_{opt}(t) = V \cdot c_{opt} \cdot [\delta(t) + \kappa \cdot H(T_{bc,opt} - t)], \quad (5.7)$$

where

$$T_{bc,opt} = \frac{\ln(10) \cdot LR_{target} - \kappa^{-1}\rho}{k(c_{opt}) - r}. \quad (5.8)$$

The resulting concentration profile, given by the solution of (5.1), is

$$C_{bc,opt}(t) = \begin{cases} c_{opt} & t \leq T_{bc,opt} \\ c_{opt}e^{-\kappa(t-T_{bc,opt})} & t > T_{bc,opt}. \end{cases} \quad (5.9)$$

The target log-reduction  $LR_{target}$  of the microbial population will be achieved at time

$$T^* = T_{bc,opt} + \frac{1}{\kappa} \cdot \ln\left(\frac{c_{opt}}{zMIC}\right), \quad (5.10)$$

and the corresponding AUC is

$$AUC_{bc,opt} = \left[ \kappa^{-1} + \frac{\ln(10) \cdot LR_{target} - \kappa^{-1}\rho}{k(c_{opt}) - r} \right] \cdot c_{opt}. \quad (5.11)$$

(ii) If  $\rho \geq \ln(10)LR_{target} \cdot \kappa$ , the solution of Problem 2 is given by

$$d_{opt}(t) = Vc^*\delta(t),$$

where  $c^*$  is the solution of the equation

$$\int_{zMIC}^{c^*} \frac{k(u) - r}{u} du = \ln(10)LR_{target} \cdot \kappa, \quad (5.12)$$

so that

$$C_{bc,opt}(t) = c^*e^{-\kappa t}.$$

The target microbial population will be reached at time

$$T^* = \frac{1}{\kappa} \cdot \ln\left(\frac{c^*}{zMIC}\right),$$

and

$$AUC_{bc,opt} = \kappa^{-1}c^*.$$

We thus see that:

(i) If  $\rho < \ln(10)LR_{target} \cdot \kappa$ , corresponding to sufficiently high decay rate of the antimicrobial, bolus+continuous dosing schedule maintains the *same* constant concentration  $c_{opt}$  as the ideal concentration profile  $C_{opt}(t)$  of Theorem 1, but for shorter time duration. Indeed from (3.3) and (5.8) we have

$$T_{opt} - T_{bc,opt} = \frac{\tau}{\ln(2)} \cdot \frac{\rho}{k(c_{opt}) - r} > 0. \quad (5.13)$$

We note also that, since  $c_{opt}$  maximizes the function  $f_r(c)$  given by (3.8), we have the inequality

$$\rho = \int_{zMIC}^{c_{opt}} \frac{k(u) - r}{u} du \leq (c_{opt} - zMIC) \cdot \frac{k(c_{opt}) - r}{c_{opt}}, \quad (5.14)$$

so that (5.13) implies

$$0 < T_{opt} - T_{bc,opt} \leq \frac{\tau}{\ln(2)} \cdot \left(1 - \frac{zMIC}{c_{opt}}\right),$$

which, in particular, implies that, as the antimicrobial half-life  $\tau$  becomes short,  $T_{bc,opt}$  converges to  $T_{opt}$ , so that the concentration profile induced by the optimal bolus+continuous schedule approaches the ideal optimal schedule  $C_{opt}(t)$ . The *AUC* achieved by the optimal bolus+continuous schedule will of course be higher than that obtained using the ideal concentration profile attaining the same log-reduction  $LR_{target}$ . Indeed from (3.4),(5.11) and (5.14) we have

$$AUC_{bc,opt} - AUC_{opt} = \frac{\tau}{\ln(2)} \cdot \left(1 - \frac{\rho}{k(c_{opt}) - r}\right) c_{opt} \geq \frac{\tau}{\ln(2)} \cdot zMIC. \quad (5.15)$$

As  $\tau$  becomes small, (5.15) shows that the  $AUC_{bc,opt}$  approaches  $AUC_{opt}$ .

(ii) If  $\rho \geq \ln(10)LR_{target} \cdot \kappa$ , corresponding to a slow decay rate of the antimicrobial, the optimal dosing schedule consists of a single bolus dose raising the antimicrobial concentration to the value  $c^*$  at time  $t = 0$ . From (5.12) it follows that, as  $\kappa \rightarrow 0$ ,

$$c^* = zMIC + \frac{\ln(10)LR_{target}}{k'(zMIC)} \cdot \kappa + o(\kappa),$$

so that for small  $\kappa$  (long antimicrobial half-life) the optimal bolus dose raises the concentration to slightly above the pharmacodynamic minimal inhibitory concentration  $zMIC$ .

To begin the analysis leading to Theorem 2, we calculate the values  $LR_{max}$  and *AUC* corresponding to a bolus+continuous dosing schedule.



**Lemma 2.** Consider a bolus+continuous schedule  $d_{bc}(t)$  (see (5.4)), with  $\bar{c} > zMIC$ , and the induced antimicrobial concentration profile  $C_{bc}(t)$  (see (5.5)). Then:

(i) The maximal log-reduction corresponding to this concentration profile is

$$LR_{max} = \frac{1}{\ln(10)} [T_{bc} \cdot (k(\bar{c}) - r) + \kappa^{-1}\phi(\bar{c})], \quad (5.16)$$

where the function  $\phi(c)$  is defined by:

$$\phi(c) = \int_{zMIC}^c \frac{k(u) - r}{u} du. \quad (5.17)$$

(ii) The AUC corresponding to this dosage schedule is

$$AUC = [\kappa^{-1} + T_{bc}] \cdot \bar{c}. \quad (5.18)$$

*Proof.* (i) By (2.11), the log-reduction of the microbial load corresponding to (5.5), at time  $T$ , is

$$LR(T) = \frac{1}{\ln(10)} \cdot \int_0^T [k(C_{bc}(t)) - r] dt,$$

hence

$$T < T_{bc} \Rightarrow LR'(T) = k(C_{bc}(T)) - r = k(\bar{c}) - r > 0,$$

and

$$\lim_{T \rightarrow \infty} LR'(T) = \lim_{T \rightarrow \infty} (k(C_{bc}(T)) - r) = \lim_{T \rightarrow \infty} (k(\bar{c}e^{-\kappa(T-T_{bc})}) - r) = -r < 0.$$

We thus have that  $LR(T)$  is an increasing function for  $T < T_{bc}$ , and a decreasing function for sufficiently large  $T$ , so that its maximum attained at some  $T^* > T_{bc}$  satisfying  $LR'(T^*) = 0$ , that is

$$\begin{aligned} k(C(T^*)) - r = 0 &\Leftrightarrow C_{bc}(T^*) = zMIC \Leftrightarrow \bar{c}e^{-\kappa(T^*-T_{bc})} = zMIC \\ &\Leftrightarrow T^* = T_{bc} + \frac{1}{\kappa} \cdot \ln\left(\frac{\bar{c}}{zMIC}\right). \end{aligned}$$

Using the change of variable  $u = \bar{c}e^{-\kappa(t-T_{bc})}$  in the integral below, we conclude

that

$$\begin{aligned}
\ln(10) \cdot LR_{max} &= \ln(10) \cdot \max_{T>0} LR(T) = \ln(10) \cdot LR(T^*) \\
&= T_{bc} \cdot (k(\bar{c}) - r) + \int_{T_{bc}}^{T^*} [k(\bar{c}e^{-\kappa(t-T_{bc})}) - r] dt \\
&= T_{bc} \cdot (k(\bar{c}) - r) + \frac{1}{\kappa} \int_{\bar{c}e^{-\kappa(T^*-T_{bc})}}^{\bar{c}} \frac{k(u) - r}{u} du \\
&= T_{bc} \cdot (k(\bar{c}) - r) + \frac{1}{\kappa} \int_{zMIC}^{\bar{c}} \frac{k(u) - r}{u} du \\
&= T_{bc} \cdot (k(\bar{c}) - r) + \kappa^{-1} \phi(\bar{c}),
\end{aligned}$$

where the function  $\phi$  is defined by (5.17).

(ii) Using (5.2), the *AUC* corresponding to the concentration profile generated by the dosing schedule (5.4) is given by

$$AUC = V^{-1} \kappa^{-1} \int_0^\infty d(t) dt = V^{-1} \kappa^{-1} [V\bar{c} + \kappa V \bar{c} T_{bc}] = [\kappa^{-1} + T_{bc}] \bar{c}.$$

□

*Proof of Theorem 2.* By (5.16), in order to achieve a given log-reduction  $LR_{target}$  using a dosing schedule of the form (5.4), the parameters  $\bar{c}, T_{bc}$  defining this schedule must satisfy the constraint  $LR_{max}[C] = LR_{target}$ , or

$$T_{bc} \cdot (k(\bar{c}) - r) + \kappa^{-1} \phi(\bar{c}) = \ln(10) \cdot LR_{target}. \quad (5.19)$$

We need to minimize the expression (5.18) over  $(\bar{c}, T_{bc})$ , under the constraints (5.19) and

$$\bar{c} \geq zMIC, \quad T_{bc} \geq 0. \quad (5.20)$$

The constraint (5.19) can be written as

$$T_{bc} = \frac{\ln(10) \cdot LR_{target} - \kappa^{-1} \phi(\bar{c})}{k(\bar{c}) - r}, \quad (5.21)$$

and the inequality constraints (5.20) imply that  $\bar{c}$  must satisfy

$$zMIC \leq \bar{c} \leq \phi^{-1}(\ln(10) LR_{target} \cdot \kappa) = c^*, \quad (5.22)$$

where  $c^*$  is the solution of (5.12).

Substituting (5.21) into (5.18) we get

$$AUC = AUC(\bar{c}) = \left[ \kappa^{-1} + \frac{\ln(10) \cdot LR_{target} - \kappa^{-1}\phi(\bar{c})}{k(\bar{c}) - r} \right] \cdot \bar{c}, \quad (5.23)$$

which must be minimized over  $\bar{c}$  satisfying (5.22). Noting that the expression (5.23) goes to  $+\infty$  when  $\bar{c} \rightarrow zMIC$ , we see that the minimum is attained either at (a) an interior point of the interval (5.22), or (b) at  $\bar{c} = c^*$ .

If  $c_{opt} < c^*$ , then since  $c_{opt}$  is the maximizer of  $f_r(c)$  given by (3.8), we have

$$\begin{aligned} & \int_{c_{opt}}^{c^*} \frac{k(u) - r}{u} du < (c^* - c_{opt}) \cdot \frac{k(c_{opt}) - r}{c_{opt}} \\ \Leftrightarrow & \phi(c^*) - \phi(c_{opt}) < \frac{c^* - c_{opt}}{c_{opt}} \cdot (k(c_{opt}) - r) \\ \Leftrightarrow & \left[ \kappa^{-1} + \frac{\ln(10) \cdot LR_{target} - \kappa^{-1}\phi(c_{opt})}{k(c_{opt}) - r} \right] \cdot c_{opt} < \kappa^{-1}c^* \\ \Leftrightarrow & AUC(c_{opt}) < AUC(c^*), \end{aligned}$$

so that the minimum of  $AUC(\bar{c})$  in the interval (5.22) is attained at an interior point, at which  $AUC'(\bar{c})$  must vanish, leading to

$$\begin{aligned} AUC'(\bar{c}) &= \kappa^{-1} + \frac{-\kappa^{-1}\phi'(\bar{c})(k(\bar{c}) - r) - [\ln(10) \cdot LR_{target} - \kappa^{-1}\phi(\bar{c})]k'(\bar{c})}{(k(\bar{c}) - r)^2} \cdot \bar{c} \\ &+ \frac{\ln(10) \cdot LR_{target} - \kappa^{-1}\phi(\bar{c})}{k(\bar{c}) - r} = 0 \\ \Leftrightarrow & \frac{[\ln(10) \cdot LR_{target} - \kappa^{-1}\phi(\bar{c})][k(\bar{c}) - r - k'(\bar{c}) \cdot \bar{c}]}{(k(\bar{c}) - r)^2} = 0 \\ \Leftrightarrow & k(\bar{c}) - r - k'(\bar{c}) \cdot \bar{c} = 0 \Leftrightarrow \bar{c} = c_{opt}. \end{aligned}$$

Thus, from (5.21) we get (5.8), and from (5.18) we get (5.11).

On the other hand, if  $c_{opt} \geq c^*$ , the above calculation shows that the derivative of  $AUC(\bar{c})$  does not vanish in the interior of the interval (5.22), so that the minimum is attained at  $\bar{c} = c^*$ , proving part (ii) of the theorem.  $\square$

## 6 Optimal bolus+continuous dosing in the case of a Hill-type pharmacodynamic function

We now apply the results of Theorem 2 to the case in which  $k(c)$  is a Hill-type function (2.6), and provide numerical examples of the results obtained.

An explicit evaluation of the integral in (5.17) gives

$$\phi(c) = \frac{r}{\gamma} \cdot \ln \left( \frac{\left(1 + \left(\frac{c}{C_{50}}\right)^\gamma\right)^\alpha}{\left(\frac{c}{C_{50}}\right)^\gamma} \cdot \frac{(\alpha - 1)^{\alpha-1}}{\alpha^\alpha} \right),$$

hence, using (4.1),

$$\rho = \phi(c_{opt}) = \frac{r}{\gamma} \cdot \ln \left( \frac{\left(\frac{\gamma+1}{2} + \sqrt{\left(\frac{\gamma-1}{2}\right)^2 + \frac{\gamma}{\alpha}}\right)^\alpha}{\frac{\gamma-1}{2} \cdot \alpha + 1 + \sqrt{\left(\frac{\gamma-1}{2} \cdot \alpha\right)^2 + \gamma \cdot \alpha}} \right),$$

and  $c^*$  is the solution of

$$\frac{\left(1 + \left(\frac{c^*}{C_{50}}\right)^\gamma\right)^\alpha}{\left(\frac{c^*}{C_{50}}\right)^\gamma} = 10^{LR_{target} \cdot \frac{\kappa\gamma}{r}} \cdot \frac{\alpha^\alpha}{(\alpha - 1)^{\alpha-1}}. \quad (6.1)$$

The condition  $\rho < \ln(10) \cdot LR_{target} \cdot \kappa$  holds iff

$$\tau < T_2 \cdot \gamma \cdot \ln(10) \cdot LR_{target} \cdot \left[ \ln \left( \frac{\left(\frac{\gamma+1}{2} + \sqrt{\left(\frac{\gamma-1}{2}\right)^2 + \frac{\gamma}{\alpha}}\right)^\alpha}{\frac{\gamma-1}{2} \cdot \alpha + 1 + \sqrt{\left(\frac{\gamma-1}{2} \cdot \alpha\right)^2 + \gamma \cdot \alpha}} \right) \right]^{-1}. \quad (6.2)$$

We thus have:

- If (6.2) holds, that is the antimicrobial half-life is sufficiently short, then the solution of Problem 2 is the bolus+continuous schedule (5.7),

where  $c_{opt}$  is given by (4.1) and  $T_{bc,opt}$  is given by

$$\frac{T_{bc,opt}}{T_2} = \frac{1}{\ln(2)(\alpha - 1)} \cdot \left( 1 + \frac{\alpha}{\frac{\gamma-1}{2} \cdot \alpha + \sqrt{\left(\frac{\gamma-1}{2} \cdot \alpha\right)^2 + \gamma \cdot \alpha}} \right) \\ \times \left[ \ln(10)LR_{target} - \frac{1}{\gamma} \cdot \ln \left( \frac{\left( \frac{\gamma+1}{2} + \sqrt{\left(\frac{\gamma-1}{2}\right)^2 + \frac{\gamma}{\alpha}} \right)^\alpha}{\frac{\gamma-1}{2} \cdot \alpha + 1 + \sqrt{\left(\frac{\gamma-1}{2} \cdot \alpha\right)^2 + \gamma \cdot \alpha}} \right) \cdot \frac{\tau}{T_2} \right].$$

Note that the value  $T_{bc,opt}$  does not depend on the half-saturation constant  $C_{50}$ .

- If the reverse inequality to (6.2) holds, that is if the antimicrobial half-life is sufficiently long, then the solution of Problem 2 is a single bolus dose  $Vc^*$ , where  $c^*$  is given by (6.1).

Tables 3,4 present numerical results regarding optimal bolus+continuous schedules, using the above formulae, which can be compared with the results concerning the ideal concentration profile in Table 2, for parameter values which are in a range relevant to applications. In Table 3 it is assumed that the ratio of the antimicrobial half-life to the microbial doubling time is  $\frac{\tau}{T_2} = 4$ , while in Table 4 we take slower antimicrobial decay,  $\frac{\tau}{T_2} = 2$ . For all parameter values considered, the condition (6.2) holds, so that the optimal schedule includes both a bolus and a continuous infusion. Comparing the  $AUC$  obtained in Table 3 with the ideal ones in Table 2, we observe that, although, as expected, the value  $AUC_{bc,opt}$  values attained by the optimal bolus+continuous schedule are higher than  $AUC_{opt}$ , in most cases they lie within 25% of that value, with the exception of extreme cases of high Hill coefficient  $\gamma$  and antimicrobial potency  $\alpha$  (e.g. for  $\gamma = 5, \alpha = 6$ ,  $AUC_{bc,opt}$  is 67.5% than  $AUC_{opt}$ ). For shorter antimicrobial half-lives, as in Table 4, the  $AUC_{bc,opt}$  is even closer to  $AUC_{opt}$ . In general, we can conclude that for realistic parameter values, the optimal bolus+continuous dosing schedule attains outcomes which are quite close to the ideal one. As an example, in figure 4 we compare the ideal optimal concentration curve and the concentration curve induced by the optimal bolus+continuous schedule, and the corresponding microbial population, using parameters as in the example of [4], with parameters fitting the antibacterial Tobramycin applied to *Pseudomonas aeruginosa* ATCC 27853 (see figure caption for parameter values). The duration




Figure 4: Left: the ideal optimal antimicrobial concentration profile (blue dashed line), and the concentration profile induced by the optimal bolus+continuous schedule (red line). Right: The corresponding microbial populations relative to the initial population. Parameters, corresponding to the example from [4] of Tobramycin applied to *Pseudomonas aeruginosa*, are:  $C_{50} = 4.187 \frac{mg}{L}$ ,  $k_{max} = 7.115 h^{-1}$ ,  $\gamma = 0.416$ ,  $r = 0.995 h^{-1}$ ,  $\kappa = 0.333 h^{-1}$ ,  $LR_{target} = 7$ .

of infusion in the optimal bolus+continuous schedule is  $T_{bc} = 31.3$  hours, slightly shorter than the duration  $T_{opt} = 33.0$  of the ideal optimal concentration profile. For the ideal concentration profile, the bacterial population reaches the target (eradication) value  $10^{-7}B_0$  at  $t = T_{opt}$ , while for the optimal bolus+continuous schedule the target value is reached at time  $T^* = 34.8$  hours (as given by (5.10)), that is 3.5 hours after antimicrobial infusion is ended. The  $AUC$  corresponding to the optimal bolus+continuous schedule is  $5.82 \frac{mg \cdot h}{L}$ , only 4% higher than the ideal optimal  $AUC_{opt} = 5.59 \frac{mg \cdot h}{L}$ .

## 7 Discussion

The results obtained in this work provide a a baseline and a reference point for evaluating the efficient use of antimicrobials. Theorem 1 describes the ideal concentration profile leading to eradication of the microbial population, with a minimal  $AUC$  - which consists of a constant concentration  $c_{opt}$  applied over a period of duration  $T_{opt}$ . We provided simple equations allowing to

Optimal duration  $\frac{T_{bc}}{T_2}$

		$\alpha$				
		2	3	4	5	6
$\gamma$	0.5	95.7	59.5	47.0	40.7	36.7
	1	53.5	28.9	20.2	15.7	12.8
	2	35.4	17.13	10.8	7.5	5.5
	3	30.3	14.3	8.8	6.0	4.3
	4	28.0	13.2	8.1	5.5	4.0
	5	26.8	12.6	7.8	5.3	3.9

$\frac{AUC_{bc,opt}}{T_2 \cdot C_{50}}$

		$\alpha$				
		2	3	4	5	6
$\gamma$	0.5	265.7	46.4	17.6	9.0	5.5
	1	143.1	47.4	26.0	17.3	12.8
	2	84.7	37.6	24.3	18.2	14.7
	3	66.1	32.2	22.0	17.2	14.3
	4	57.1	29.1	20.5	16.3	13.8
	5	51.7	27.1	19.4	15.6	13.4

Table 3: Optimal bolus+continuous dosage plans for achieving log-reduction  $LR_{target} = 7$ , when the half-life of the antimicrobial satisfies  $\frac{\tau}{T_2} = 4$ , for different values of  $\alpha = \frac{k_{max}}{r}$  and of the Hill exponent  $\gamma$ . The concentration  $c_{opt}$  to be maintained is the same as is Table 2. Top: Optimal duration of dosing, Bottom: value of  $AUC$  attained by the optimal schedule

Optimal duration  $\frac{T_{bc}}{T_2}$

		$\alpha$				
		2	3	4	5	6
$\gamma$	0.5	97.1	61.0	48.6	42.2	38.3
	1	54.8	30.3	24.6	17.2	14.4
	2	36.5	18.4	12.1	8.9	6.9
	3	31.3	15.4	10.0	7.2	5.5
	4	28.9	14.1	9.1	6.6	5.0
	5	27.6	24.1	8.7	6.3	4.8

$\frac{AUC_{bc,opt}}{T_2 \cdot C_{50}}$

		$\alpha$				
		2	3	4	5	6
$\gamma$	0.5	261.8	45.4	17.2	8.8	5.3
	1	139.3	45.4	24.6	16.3	11.9
	2	81.1	34.8	22.0	16.2	12.8
	3	62.6	29.3	19.4	14.7	12.0
	4	53.7	26.1	17.7	13.6	11.2
	5	48.4	24.1	16.6	12.9	10.7

Table 4: Optimal bolus+continuous dosage plans for achieving log-reduction  $LR_{target} = 7$ , when the half-life of the antimicrobial satisfies  $\frac{\tau}{T_2} = 2$ , for different values of  $\alpha = \frac{k_{max}}{r}$  and of the Hill exponent  $\gamma$ . The concentration  $c_{opt}$  to be maintained is the same as is Table 2. Top: Optimal duration of dosing, Bottom: value of  $AUC$  attained by the optimal schedule



compute the key quantities  $c_{opt}$  and  $T_{opt}$  for an arbitrary pharmacodynamic function  $k(c)$ , and explicit expressions for these quantities in the case of the widely-used Hill-type function (see (4.1),(4.2)).

Since the ‘ideal’ concentration profile is not strictly feasible due to pharmacokinetic constraints, we have also considered the question of determining an optimal bolus+continuous dosing schedule, assuming first order pharmacokinetics. Our results show that the optimal dosing leads to the *same* constant concentration  $c_{opt}$  as for the ideal concentration profile during a dosing period  $T_{bc,opt} < T_{opt}$ . Our numerical comparisons show that the results obtained using this optimal bolus+continuous dosing plan are in most cases only slightly inferior to those obtained using the ‘ideal’ concentration profile.

We note that while the ‘ideal’ concentration profile was proved to be optimal among *all* concentration profiles, in the investigation of dosing plans under pharmacokinetic constraints we restricted ourselves in advance to bolus+continuous plans with constant dosing rate following the loading dose. In fact we conjecture that no dosing schedule with a non-constant dosing rate can improve upon the performance of the dosing plans considered, but leave a full treatment of this question to future work.

In practice, the administration of a continuous dosing schedule requires the use of intravenous infusion, infusion pumps, or sustained/controlled release formulations. An intermittent dosing schedule, involving a series of bolus doses, is often opted for [10]. It is intuitively obvious, however, and can be formally proved, that sufficiently frequent intermittent infusions, with appropriate doses, can be used to approximate a bolus+continuous schedule, so that our results concerning the optimal bolus+continuous schedule are also relevant to the design of intermittent schedules, and in particular can be used to assess the degree to which a proposed intermittent schedule can be improved upon by increasing the frequency of dosing or by shifting to continuous infusion.

The models which we employed in the study are standard ones, which are widely applied in the quantitative literature on antimicrobial pharmacology. However, as always with mathematical modelling, it is important to take into account the limitations of the models employed, and their possible implications regarding the conclusions drawn using the model. We now discuss several such limitations, which suggest issues which should be addressed in future work.

Our investigation of optimal dosing under pharmacokinetic constraints was restricted to a basic one-compartment model with first order kinetics.

It is also important to consider optimal dosing plans in the context of more elaborate models. In particular, if the antimicrobial enters a compartment distinct from the site of action, the resulting delay implies that an initial bolus dose cannot immediately raise the concentration at the site of action to an optimal level. Implications of this fact for the optimization of dosing schedules merit systematic study.

Some of the works on dynamical modelling of microbial dynamics under the effect of antimicrobials, in particular the more theoretical studies, include mechanisms which are absent from the basic model considered here. One such mechanism is density-dependence of the microbial population growth, which will be relevant if this population reaches a size at which resource limitation reduces its growth rate [1, 3, 12, 15, 16, 18, 29, 33, 41, 46]. Another element which influences microbial dynamics is immune response, and if the strength of immune suppression is comparable to that of the antimicrobial, it might be important to include an immune system component in the model [12, 13, 14, 41]. It is important to examine whether and how the incorporation of these additional mechanisms into the models modifies the conclusions obtained here. Since more elaborate models include nonlinearities and/or are higher dimensional, such extension of our investigation is non-trivial. In particular general analytical results may not always be feasible, so that it might be necessary to resort to numerical simulation and optimization [1, 6, 7, 13, 14, 16, 33, 34, 40]. The analytical results presented here should form a useful point of reference for comparison with results obtained using extended models.

The effort to prevent antimicrobial resistance is an important motivation for the efficient use of antimicrobial agents, which has been studied here. However the model we employed does not directly address this issue, as do models which include a separate compartment for resistant strains which may arise due to mutations [1, 12, 13, 16, 19, 22, 24, 28, 33, 39, 46]. This can lead to additional considerations regarding optimization of antimicrobial use, which are beyond our scope here.

Finally, we note that our analyses assume known pharmacodynamic and pharmacokinetic parameters, but these parameters themselves will vary among individuals, and the design of treatment plans must also take into account this heterogeneity, a fact which has led to the development of population PK/PD modelling [11, 43]. Incorporating the insights obtained from the results in the present work into the population perspective remains a task for future research.

## References

- [1] Ali, A., Imran, M., Sial, S., & Khan, A. (2022). Effective antimicrobial dosing in the presence of resistant strains. *PLoS ONE*, 17(10), e0275762.
- [2] Austin, D. J., White, N. J., & Anderson, R. M. (1998). The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. *Journal of Theoretical Biology*, 194(3), 313-339.
- [3] Bhagunde, P. R., Nikolaou, M., & Tam, V. H. (2015). Modeling heterogeneous bacterial populations exposed to antibiotics: The logistic dynamics case. *AIChE Journal*, 61(8), 2385-2393.
- [4] Bouvier d'Yvoire, M. J., & Maire, P. H. (1996). Dosage regimens of antibacterials. *Clinical Drug Investigation*, 11(4), 229-239.
- [5] Bulitta, J. B., Hope, W. W., Eakin, A. E., Guina, T., Tam, V. H., Louie, A., Drusano, G.L., & Hoover, J. L. (2019). Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans. *Antimicrobial Agents and Chemotherapy*, 63(5), e02307-18.
- [6] Cicchese, J. M., Pienaar, E., Kirschner, D. E., & Linderman, J. J. (2017). Applying optimization algorithms to tuberculosis antibiotic treatment regimens. *Cellular and Molecular Bioengineering*, 10, 523-535.
- [7] Colin, P. J., Eleveld, D. J., & Thomson, A. H. (2020). Genetic Algorithms as a Tool for Dosing Guideline Optimization: Application to Intermittent Infusion Dosing for Vancomycin in Adults. *CPT: Pharmacometrics & Systems Pharmacology*, 9(5), 294-302.
- [8] Corvaisier, S., Maire, P. H., Bouvier d'Yvoire, M. Y., Barbaut, X., Bleyzac, N., Jelliffe, R. W. (1998). Comparisons between antimicrobial pharmacodynamic indices and bacterial killing as described by using the Zhi model. *Antimicrobial Agents and Chemotherapy*, 42(7), 1731-1737.
- [9] Czock, D., & Keller, F. (2007). Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. *Journal of Pharmacokinetics and Pharmacodynamics*, 34(6), 727-751.

- [10] Derendorf, H., & Schmidt, S. (2019). Rowland and Tozer’s clinical pharmacokinetics and pharmacodynamics: concepts and applications, Wolters Kluwer.
- [11] de Velde, F., Mouton, J. W., de Winter, B. C., van Gelder, T., & Koch, B. C. (2018). Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. *Pharmacological Research*, 134, 280-288.
- [12] Geli, P., Laxminarayan, R., Dunne, M., & Smith, D. L. (2012). “One-size-fits-all”? Optimizing treatment duration for bacterial infections. *PLoS ONE*, 7(1), e29838.
- [13] Goranova, M., Ochoa, G., Maier, P., & Hoyle, A. (2022). Evolutionary optimisation of antimicrobial dosing regimens for bacteria with different levels of resistance. *Artificial Intelligence in Medicine*, 102405.
- [14] Hoyle, A., Cairns, D., Paterson, I., McMillan, S., Ochoa, G., & Desbois, A. P. (2020). Optimising efficacy of antimicrobials against systemic infection by varying dosage quantities and times. *PLoS computational biology*, 16(8), e1008037.
- [15] Kesisoglou, I., Tam, V. H., Tomaras, A. P., & Nikolaou, M. (2022). Discerning in vitro pharmacodynamics from OD measurements: A model-based approach. *Computers & chemical engineering*, 158, 107617.
- [16] Khan, A., & Imran, M. (2018). Optimal dosing strategies against susceptible and resistant bacteria. *Journal of Biological Systems*, 26(01), 41-58.
- [17] Leszczyński, M., Ledzewicz, U., & Schättler, H. (2020). Optimal control for a mathematical model for chemotherapy with pharmacometrics. *Mathematical Modelling of Natural Phenomena*, 15, 69.
- [18] Levin, B. R., & Udekwi, K. I. (2010). Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments. *Antimicrobial Agents and Chemotherapy*, 54(8), 3414-3426.
- [19] Lipsitch, M., & Levin, B. R. (1997). The population dynamics of antimicrobial chemotherapy. *Antimicrobial Agents and Chemotherapy*, 41(2), 363-373.

- [20] Luterbach, C. L., & Rao, G. G. (2022). Use of pharmacokinetic/pharmacodynamic approaches for dose optimization: a case study of plazomicin. *Current Opinion in Microbiology*, 70, 102204.
- [21] Macheras, P., & Iliadis, A. (2016). *Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics: homogeneous and heterogeneous approaches*, Springer.
- [22] Marrec, L., & Bitbol, A. F. (2020). Resist or perish: fate of a microbial population subjected to a periodic presence of antimicrobial. *PLoS Computational Biology*, 16(4), e1007798.
- [23] Meibohm, B., & Derendorf, H. (1997). Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. *International Journal of Clinical Pharmacology and Therapeutics*, 35(10), 401-413.
- [24] Morsky, B., & Vural, D. C. (2022). Suppressing evolution of antibiotic resistance through environmental switching. *Theoretical Ecology*, 15(2), 115-127.
- [25] Mouton, J. W., & Vinks, A. A. (2005). PK-PD modelling of antibiotics in vitro and in vivo using bacterial growth and kill kinetics: the zMIC vs stationary concentrations. *Clinical Pharmacokinetics*, 44, 201-10.
- [26] Mueller, M., de la Pena, A., & Derendorf, H. (2004). Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. *Antimicrobial Agents and Chemotherapy*, 48(2), 369-377.
- [27] Murray, C. J., Ikuta, K. S., Sharara, F., et al (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*, 399(10325), 629-655.
- [28] Nielsen, E. I., & Friberg, L. E. (2013). Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs. *Pharmacological Reviews*, 65(3), 1053-1090.
- [29] Nikolaou, M., & Tam, V. H. (2006). A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations. *Journal of Mathematical Biology*, 52(2), 154-182.

- [30] Nikolaou, M., Schilling, A. N., Vo, G., Chang, K. T., & Tam, V. H. (2007). Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents. *Annals of Biomedical Engineering*, 35(8), 1458-1470.
- [31] Onufrak, N. J., Forrest, A., & Gonzalez, D. (2016). Pharmacokinetic and pharmacodynamic principles of anti-infective dosing. *Clinical Therapeutics*, 38(9), 1930-1947.
- [32] Owens, R. C., Nightingale, C. H., & Ambrose, P. G. (Eds.). (2004). *Antibiotic optimization: concepts and strategies in clinical practice*. CRC Press.
- [33] Paterson, I. K., Hoyle, A., Ochoa, G., Baker-Austin, C., & Taylor, N. G. (2016). Optimising antimicrobial usage to treat bacterial infections. *Scientific Reports*, 6(1), 1-10.
- [34] Peña-Miller, R., Lähnemann, D., Schulenburg, H., Ackermann, M., & Beardmore, R. (2012). Selecting against antibiotic-resistant pathogens: optimal treatments in the presence of commensal bacteria. *Bulletin of Mathematical Biology*, 74(4), 908-934.
- [35] Rayner, C. R., Smith, P. F. et. al. (2021). Model informed drug development for anti-infectives: state of the art and future. *Clinical Pharmacology & Therapeutics*, 109(4), 867-891.
- [36] Rao, G. G., & Landersdorfer, C. B. (2021). Antibiotic pharmacokinetic/pharmacodynamic modelling: zMIC, pharmacodynamic indices and beyond. *International Journal of Antimicrobial Agents*, 58(2), 106368.
- [37] Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F., & Levin, B. R. (2004). Pharmacodynamic functions: a multiparameter approach to the design of antimicrobial treatment regimens. *Antimicrobial Agents and Chemotherapy*, 48(10), 3670-3676.
- [38] Rotschafer, J. C., Andes, D. R., & Rodvold, K. A. (Eds.). (2016). *Antibiotic Pharmacodynamics*. Humana press.

- [39] Singh, G., Orman, M. A., Conrad, J. C., & Nikolaou, M. (2023). Systematic design of pulse dosing to eradicate persister bacteria. *PLoS Computational Biology*, 19(1), e1010243.
- [40] Smith, N. M., Lenhard, J. R. et. al. (2020). Using machine learning to optimize antimicrobial combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant *Acinetobacter baumannii*. *Clinical Microbiology and Infection*, 26(9), 1207-1213.
- [41] Tindall, M., Chappell, M. J., & Yates, J. W. (2022). The ingredients for an antimicrobial mathematical modelling broth. *International Journal of Antimicrobial Agents*, 106641.
- [42] Ventola, C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. *Pharmacy and Therapeutics*, 40(4), 277.
- [43] Vinks, A. A., Derendorf, H., & Mouton, J. W. (Eds.). (2014). *Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics*. Springer.
- [44] Wen, X., Gehring, R., Stallbaumer, A., Riviere, J. E., & Volkova, V. V. (2016). Limitations of zMIC as sole metric of pharmacodynamic response across the range of antimicrobial susceptibilities within a single bacterial species. *Scientific Reports*, 6(1), 1-8.
- [45] Zhi, J., Nightingale, C. H., & Quintiliani, R. (1988). Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to *Pseudomonas aeruginosa*. *Journal of pharmacokinetics and biopharmaceutics*, 16, 355-375.
- [46] Zilonova, E. M., & Bratus, A. S. (2016). Optimal strategies in antibiotic treatment of microbial populations. *Applicable Analysis*, 95(7), 1534-1547.